The short version
- Why people research itLean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- What the evidence isA real pharmaceutical program with a real result.
- What to watchTendon or joint pain in the treated limb that builds as the muscle grows.
How ACE-083 works
ACE-083 is the rarest thing in this catalog: a compound with two completed randomized human trials, both of which met their primary endpoint and failed anyway. That sentence is the page, and almost nowhere selling this molecule says it.
What the molecule is. It is not a peptide. It is a locally-acting follistatin-based fusion protein, and the engineering has two halves that pull in opposite directions Pearsall 2019.
It sequesters myostatin and related TGF-beta ligands locally, so hypertrophy is confined to the injected muscle rather than being systemic.
- Injectable
On the goal map: Lean-mass protection while cutting (Lose fat)
Research on ACE-0835 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Phase 2 trials — muscle volume increased, but strength and function did not follow.
Human clinical evidence
A real pharmaceutical program with a real result. Acceleron ran phase 2 trials of ACE-083 in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease. It reliably increased muscle volume in the injected muscle — that part worked — but did not produce corresponding improvements in strength or function, and development was discontinued.
That dissociation is the finding worth carrying: bigger muscle and stronger muscle are not the same endpoint, and this is one of the cleanest demonstrations of it in the literature.
Correlative data
Essentially no community use, and that absence is itself informative — it was never widely available after Acceleron shut the program, so unlike most compounds here there is no anecdotal record to weigh against the trial. What you see is what there is: a well-run phase 2 that produced measurable hypertrophy and no functional gain.
How the mechanism reads
A locally-acting myostatin/activin ligand trap.
MechanisticThe local design is what made it interesting and what the trial result complicates: hypertrophy without functional gain suggests the added tissue was not contributing normally, which is a caution for every myostatin-targeting approach.
Mechanistic
Sources
- Pearsall RS, Davies MV, Cannell M, Li J, Widrick J, Mulivor AW, Wallner S, Troy ME, Spaits M, Liharska K, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Scientific Reports 2019 · PMID 31388039
- Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle & Nerve 2018 · PMID 29486514
- Statland JM, Campbell C, Desai U, Karam C, Diaz-Manera J, Guptill JT, Korngut L, Genge A, Tawil RN, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle & Nerve 2022 · PMID 35428982
- Thomas FP, et al. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology 2022 · PMID 35545446
- Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve 2017 · PMID 27462804
- Nielsen TL, et al. Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells 2021 · PMID 33802348
- Rodgers BD, Ward CW. Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs. Endocrine Reviews 2022 · PMID 34520530
- Schneyer AL, et al. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. Journal of Clinical Endocrinology and Metabolism 2004 · PMID 15472207
- Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences 2001 · PMID 11459935
ACE-083 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- A recent tendon or muscle tear in the muscle it would be placed near.
- Skin infection or inflammation at the intended site.
- Active cancer, since TGF-beta ligand trapping also touches growth control.
- Under 18, while growth plates and tendons are still developing.
- Pregnancy, since activin and myostatin pathways guide fetal development.
What’s expected
- Local muscle fullness and tenderness in the treated muscle.
- Growth confined mostly to that muscle, by design, rather than body-wide.
- Tendons lag behind muscle size, so loaded tendons may ache.
Watch for
- Tendon or joint pain in the treated limb that builds as the muscle grows.
- Spreading redness, heat or fever around the muscle it was placed in.
- Nosebleeds or easy bruising, as ligand traps can leak into the blood.
Labs that tell you it’s working
- Cystatin C with eGFR: tracks kidney function without being faked by extra muscle the way creatinine is.
- LH & FSH: follistatin binds activin, so a falling FSH would hint at systemic leakage.
- Comprehensive Metabolic Panel: creatinine and liver enzymes both shift with muscle turnover.
- hs-CRP: separates local inflammation at the site from a systemic reaction.
Follistatin-Fc ligand trap sequestering myostatin and activin within the injected muscle; risk is local overload and systemic leak. PMID 31388039 PMID 29486514 PMID 35428982
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
ACE-083 FAQ4 common questions
- Is ACE-083 approved for human use?
- No. ACE-083 is a research compound.
- What is ACE-083 researched for?
- Lean-mass support, recovery, sleep depth, connective-tissue repair and improved body composition via the GH/IGF-1 axis.
- Which labs show whether it's doing anything?
- Cystatin C with eGFR; LH & FSH; Comprehensive Metabolic Panel; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for ACE-083: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



